Analyst Ratings For Galmed Pharmaceuticals (NASDAQ:GLMD)

Today, HC Wainwright raised its price target on Galmed Pharmaceuticals (NASDAQ:GLMD) to $24.00 per share.

Some recent analyst ratings include

• 11/15/2017-Roth Capital initiated coverage with a Buy rating.
• 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.

Recent Trading Activity for Galmed Pharmaceuticals (NASDAQ:GLMD)
Shares of Galmed Pharmaceuticals closed the previous trading session at 10.13 up +0.43 4.43% with 9.890000343322754 shares trading hands.